ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
RespireRx Pharmaceuticals Inc (CE)

RespireRx Pharmaceuticals Inc (CE) (RSPI)

0.0022
0.0002
(10.00%)
Closed February 18 3:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
0.0022
Bid
0.00
Ask
0.00
Volume
90,000
0.002 Day's Range 0.0025
0.0002 52 Week Range 0.0069
Market Cap
Previous Close
0.002
Open
0.0025
Last Trade
39260
@
0.0022
Last Trade Time
Financial Volume
US$ 224
VWAP
0.002493
Average Volume (3m)
687,328
Shares Outstanding
471,740,000
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-0.01
Revenue
-
Net Profit
-3.97M

About RespireRx Pharmaceuticals Inc (CE)

RespireRX Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, ADHD, spinal cord injury and other neurological conditions. RespireRX Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, ADHD, spinal cord injury and other neurological conditions.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
RespireRx Pharmaceuticals Inc (CE) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker RSPI. The last closing price for RespireRx Pharmaceuticals (CE) was US$0. Over the last year, RespireRx Pharmaceuticals (CE) shares have traded in a share price range of US$ 0.0002 to US$ 0.0069.

RespireRx Pharmaceuticals (CE) currently has 471,740,000 shares outstanding. The market capitalization of RespireRx Pharmaceuticals (CE) is US$943,480 . RespireRx Pharmaceuticals (CE) has a price to earnings ratio (PE ratio) of 0.00.

RSPI Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0005-18.51851851850.00270.00270.00188861760.00199024CS
4-0.0002-8.333333333330.00240.00270.00076029870.00180195CS
120.0015214.2857142860.00070.00270.00066873280.00150511CS
260.0019633.3333333330.00030.00270.00036762490.00140054CS
520.000969.23076923080.00130.00690.0002115882720.00273192CS
156-0.0147-86.98224852070.01690.01910.000264574700.00225651CS
260-0.1078-980.110.14990.000262291300.00484325CS

RSPI - Frequently Asked Questions (FAQ)

What is the current RespireRx Pharmaceuticals (CE) share price?
The current share price of RespireRx Pharmaceuticals (CE) is US$ 0.0022
How many RespireRx Pharmaceuticals (CE) shares are in issue?
RespireRx Pharmaceuticals (CE) has 471,740,000 shares in issue
What is the market cap of RespireRx Pharmaceuticals (CE)?
The market capitalisation of RespireRx Pharmaceuticals (CE) is USD 943.48k
What is the 1 year trading range for RespireRx Pharmaceuticals (CE) share price?
RespireRx Pharmaceuticals (CE) has traded in the range of US$ 0.0002 to US$ 0.0069 during the past year
What is the reporting currency for RespireRx Pharmaceuticals (CE)?
RespireRx Pharmaceuticals (CE) reports financial results in USD
What is the latest annual profit for RespireRx Pharmaceuticals (CE)?
The latest annual profit of RespireRx Pharmaceuticals (CE) is USD -3.97M
What is the registered address of RespireRx Pharmaceuticals (CE)?
The registered address for RespireRx Pharmaceuticals (CE) is 900 FOULK ROAD, SUITE 201, WILMINGTON, DELAWARE, 19803
What is the RespireRx Pharmaceuticals (CE) website address?
The website address for RespireRx Pharmaceuticals (CE) is www.respirerx.com
Which industry sector does RespireRx Pharmaceuticals (CE) operate in?
RespireRx Pharmaceuticals (CE) operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ELYSElys BMG Group Inc (CE)
US$ 0.0004
(39,900.00%)
5.14k
YRIVYangtze River Port and Logistics Ltd (CE)
US$ 0.0001
(9,900.00%)
2.39k
SIRCSolar Integrated Roofing Corporation (PK)
US$ 0.0001
(9,900.00%)
15.01M
NXTPNextPlay Technologies Inc (CE)
US$ 0.0001
(9,900.00%)
2.21k
MFLTYMissfresh Ltd (CE)
US$ 0.0001
(9,900.00%)
103
AUSAFAustralis Capital Inc (CE)
US$ 0.000001
(-99.99%)
20.5k
AGCZAndes Gold Corp (CE)
US$ 0.000001
(-99.75%)
40.14k
FVTIFortune Valley Treasures Inc (CE)
US$ 0.0015
(-99.40%)
589
EGRNFChina Evergrande Group (CE)
US$ 0.0001
(-99.01%)
5k
AHFDActive Health Foods Inc (CE)
US$ 0.000001
(-99.00%)
500k
TKMOTekumo Inc (PK)
US$ 0.0002
(-20.00%)
261.44M
GTLLGlobal Technologies Ltd (PK)
US$ 0.0003
(0.00%)
229.69M
RDARRaadr Inc (PK)
US$ 0.0008
(14.29%)
138.89M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.00305
(15.09%)
131.8M
HMBLHUMBL Inc (PK)
US$ 0.0005
(0.00%)
126.35M

RSPI Discussion

View Posts
DTGoody DTGoody 6 hours ago
I agree the possibilities are incredible! We are priced nowhere near what we should be. Somebody is going to step in with some funding in my opinion.
👍️ 5
LTListener LTListener 6 hours ago
Considering today is day 15 post SEC letter and they likely have some smallish time period to go back and forth with SEC on options, where they stand, etc.. I would hope they update shareholders soon as to the nature and intent of going forward with filings or form 15...

And it would not surprise me at all if there is a frankenstein rabbit ready to be pulled out of that hat as well. They have well connected and well off BOD/CEO/insiders that could have kept the filings up last spring and they chose not to at that time.. Presumably buying time to work in the background on heating up those irons in the fire.... And we know how valuable the ampakine platform with multiples in phase 2 and the gabakine platform with premier preclinical profile for high profile epilepsy and opioid mitigation... IMO value is 20-30 fold this measely 2 million market cap on the EM.... and that will be low once they garner clinical success in their trials..
👍️ 3
LTListener LTListener 6 hours ago
Still not much dollar volume from a few hundred bucks to a few thousand bucks here and there daily on the EM. Peanuts. There just isn't much appetite to sell at such depressed levels and buying is hard because no shares and most of us do not have accounts where we can buy anyhow.

It is time for them to get this trading with some liquidity and continually update all stakeholders to bring in more interest. They will want this trading in advance of pulling out those red hot irons from the fire. Allow for some organic appreciation, accumulation and consolidate some positions that are not paying attention or versed in where this can go in the next 3,6,12+ months...
πŸ‘οΈ0
DTGoody DTGoody 6 hours ago
They have lots of options but form 15 keeps them in compliance. But who knows what they have going on behind closed doors. Something nice could be in the works here.
πŸ‘οΈ0
DTGoody DTGoody 6 hours ago
Same here! At least until they can further along.
πŸ‘οΈ0
Lime Time Lime Time 6 hours ago
It's definitely appealing at this price and I hate repeating myself. I'd really like to see them take the Form 15 route.
πŸ‘οΈ0
LTListener LTListener 6 hours ago
Hard to say if that is the route they will take. Maybe they are in negotiation/discussion with SEC about a timeline to complete the filings that supposedly were 80% completed. I am not sure it makes much sense to be SEC registered and trading on the OTC, it only costs the company outrageous amounts of cash just for auditing/filing/fees, etc when the OTC has not shown any more liquidty whether pink current/limited/OTCxx whatever tier. Alternate reporting route makes a ton of sense and as these assets mature further maybe they can find a way to M&A onto the Nasdaq scene which is where they can maybe find the business resources they sorely need as well as the support capital to sustain expanding efforts with the neuromodulators...

I find this interesting from the shareholder letter...
"7th Annual CB1, CB2 & Cannabinoid Drug Development Summit – Arnold Lippa and Jeff Margolis presented separately on November 19, 2024. This was an industry driven summit and generated a degree of interest and a commercial proposal from a U.S. entity that is being considered."
I would be curious what the commercial proposal was... If they can strike some deal with the OSA platform that might be able to support the EndeavourRx division...
πŸ‘οΈ0
Catpole Catpole 6 hours ago
Thanks for keeping us informed!
👍️ 1
DTGoody DTGoody 6 hours ago
Thanks for the quotes as I cannot see anything with E-Trade or thinkorswim. I wish we could buy here in the U.S.
👍️ 1
Lime Time Lime Time 7 hours ago
Bid .0015
Ask .0020
πŸ‘οΈ0
DTGoody DTGoody 7 hours ago
A little slower trading here today than we had last week. Can't wait for them to file form 15 so this will start trading again. Being on this expert market really sucks.
πŸ‘οΈ0
LTListener LTListener 1 day ago
They should be easily be able to outsource the website updates and professional look for cheap. Like I said, I bet some college kids could have it done over a weekend. It is all part of the package and all works together. Professional communication and presentation leads to better interest, better interest leads to increased discussion which leads to more opportunities which leads to funding. Funding advances the pipeline and stretches the reach of the assets and leads to success which then leads back to communication and presentation of progress to new interest and collaboration and attracting resources, etc, etc...
👍️ 4
Menace212 Menace212 1 day ago
Yeah they have obviously reached notable even applaudable milestones. At their disposal they have an extensive account of research coupled by early clinical testing particularly phase 1, however being oblivious or ignorant to investor oriented outlook is inevitable for them. They have a direct need for more memebers to their team, along with divisions outside of research and conduct. They may not be a nasqad corporation yet, nevertheless they are still a publicly traded company. To maintain that appearance requires personnel or outsources to facilitate and arrange bussiness/consumer releations. However with deficiency in funds this is a plain obstacle for them no matter how much diligence they use to stay updated, things will continue to slip through the cracks. It's only 24 hours in a day discounting sleep lol. Hopefully they can close a deal, gain notable amount of funding and apply it to towards internal expansion. After obviously taking a bit home to their families don't want to play the unsympathetic tune lol, quick reminder they have yet to see a substantial pay day from this company. There's only so much time any person will reasonably allot to a project if no returns are realized. GLTA hopefully we will be graced with a ground breaking deal in the foreseeable future.
👍️ 1
bigtalan bigtalan 1 day ago
Thank you , we are all investors here not traders we believe in the research. I feel the company is trying its best they just have so much to offer and not yet have the financing in place to push forward. The little things we see as the investor that looks cheesy or not as professional as we think it should look is something I don't think they see as being that bad. With all the others on this board that have the back grounds in medical break thru, high skills in keeping up with theses types of break thru, and the ability to write it up for all of us to understand, lends alot to this board. I just pass things of concerns to Jeff so he can see how we are seeing the company and future investors might see the info that is out there. The miss steps by not keeping up with BOD , who is left here and who is nolonger involved with RSPI. The info that is old should be replaced with updated info , news , and forward direction they are striving for.
Yes Jeff is very easy to communicate with and that is a great thing we have going for us. He will listen take in what the points are and work with them.I know he is busy so I try not to take up to much time since he has alot on his plate. With updating the website yet another thing, but as many have pointed out it is out dated and needs an overhaul to shine the new info that is current.
👍️ 2
ajd ajd 1 day ago
Thanks so much for being our VOICE here ! You seem to have a good repour with Jeff, I'm sure he appreciates having you to communicate with as our spokesperson! Keep up the good work things sure seem to be looking up!!!!
👍️ 1
bigtalan bigtalan 1 day ago
Hello Jeff here is a few things people are talking about as suggestions to better the look from an investors view may help may not just thought you would like to see

I used a few of the post from today for him to see how and what we are looking at as investors . His reply to me and I summarized it to be able to post at the bottom

Thinking of new found energy and focus and eyes on this one...

They do need to spend a little effort and update that Respire website. That remains a trainwreck and if they dont have the skills to clean it up, it would not cost much at all to hire someone to do so. Having the correct management and BOD listed, updated/link shareholder letter, update the ampakine and gabakine platform summaries, update the pipeline chart, maybe have a publications tab to highlight their achievements in peer reviews, add a professional look and touch to it. Simple yet important part of how a business communicates and presents to investing public/interested collaborators and such..

I still shm at the paradox here. The company has continually traded under 3 million market valuation long before this move to the EM and during this trip on the EM. Yet internally they value the assets north of 50 million. Having multiple ampakine candidates ready for phase 2 clinical with one having DOD funds should easily be worth 10s of million minimum. Having another gabakine candidate with a superior preclinical profile having NIH funding IND enabling studies at the advanced stages of preclinicals and readying for multiple phase 1 clinical trials most likely, is also easily worth 10s of millions... I think everyone is hoping this entity is on a course correct and soon a more fair and respectable valuation for the quality of the science, the assets will emerge and provide that flexibility and resources to really push progress on the science, expand its reach and potential. Not every effort will succeed, but some very likely will and that will have a significant impact on those who need these solutions the most. GLTA

If low dosage form of this high impact ampakine is indeed viable per their publication, then it would be nice to see it added to their pipeline.

When I say the "legacy of Cortex should be ignored," I am saying it appears the majority of investors have focused on those failures to date. Cortex was premature but provided the foundation to where we are now. Some of the early papers out of UCI are referenced more than 200 times- an incredible feat, to say the least. We obviously have a whole new ballgame with RSPI which is alluded to in this paper. Lippa and Cerna are well-respected scientists in neuropharmacology which certainly should not be discounted in the valuation of RSPI.

1 more i left off



Yeah, there has certainly been alot of effort in publicizing and summarizing all the entirety of the ampakine portfolio. Obviously, the phase 2 SCI and I am guessing for as much as they reference it, there is probably a phase 2 for ADHD in the works as well. Add in the high impact ampakine for cognition in the recent publication and you have quite the platform. This is only 1/2 of the neuromodulator division and the gabakine looks to be positioned extremely well exiting IND enabling studies and IMO possibly the crown jewel of them all...

But back to the ampakine platform. I find it interesting that they have put forth so much effort on the publication front of older studies. It tells me they have some serious interest in likely a partnership JV or sale of this platform. Remember their one slide suggesting phase 2 companies get the best deals!! Would only be logical and they did attempt to sell 15 years ago in a deal with Biovail.

And to think they suggested in shareholder letter that they were looking to bring in another asset to develop... That is so illogical as they have their hands full now with all they got going on, unless... they will be handing the baton off on one or more of the platforms... IMO, that would make a lot of sense... And really what would those accepting preferred be thinking in needing 15-20 million in a payment event to unlock their payment. There must be some significant and maturing interest to even think they were in a position to have the capacity for such an investment to enter... I've read enough of all their publications and such to be of the opinion that this is jsut going to become huge in a hurry... I think it would be awesome to see this properly valued and see what else some of the esteemed scientists can get going here. Just need some help on the business end and I think this will quickly become a mid major pharma.

He thanks all and this type of feedback is very helpful. They will take the time to update the website. Unfortunately, no matter they cut it, the job falls on Jeff and you can imagine how swamped he is. But it will get done he stated GLTA
👍️ 6
LTListener LTListener 1 day ago
Yeah, there has certainly been alot of effort in publicizing and summarizing all the entirety of the ampakine portfolio. Obviously, the phase 2 SCI and I am guessing for as much as they reference it, there is probably a phase 2 for ADHD in the works as well. Add in the high impact ampakine for cognition in the recent publication and you have quite the platform. This is only 1/2 of the neuromodulator division and the gabakine looks to be positioned extremely well exiting IND enabling studies and IMO possibly the crown jewel of them all...

But back to the ampakine platform. I find it interesting that they have put forth so much effort on the publication front of older studies. It tells me they have some serious interest in likely a partnership JV or sale of this platform. Remember their one slide suggesting phase 2 companies get the best deals!! Would only be logical and they did attempt to sell 15 years ago in a deal with Biovail.

And to think they suggested in shareholder letter that they were looking to bring in another asset to develop... That is so illogical as they have their hands full now with all they got going on, unless... they will be handing the baton off on one or more of the platforms... IMO, that would make a lot of sense... And really what would those accepting preferred be thinking in needing 15-20 million in a payment event to unlock their payment. There must be some significant and maturing interest to even think they were in a position to have the capacity for such an investment to enter... I've read enough of all their publications and such to be of the opinion that this is jsut going to become huge in a hurry... I think it would be awesome to see this properly valued and see what else some of the esteemed scientists can get going here. Just need some help on the business end and I think this will quickly become a mid major pharma.
👍️ 1
meixatech meixatech 1 day ago
LT When I say the "legacy of Cortex should be ignored," I am saying it appears the majority of investors have focused on those failures to date. Cortex was premature but provided the foundation to where we are now. Some of the early papers out of UCI are referenced more than 200 times- an incredible feat, to say the least. We obviously have a whole new ballgame with RSPI which is alluded to in this paper. Lippa and Cerna are well-respected scientists in neuropharmacology which certainly should not be discounted in the valuation of RSPI.
πŸ‘οΈ0
LTListener LTListener 1 day ago
If low dosage form of this high impact ampakine is indeed viable per their publication, then it would be nice to see it added to their pipeline.
πŸ‘οΈ0
meixatech meixatech 1 day ago
Folks, I repost this. As a scientist, I am astounded at the implications, and in IMO CX1837 will be a blockbuster. Then add all the other compounds and we are looking at a multiple billion dollar company. The legacy of Cortex should be ignored.

Curr Alzheimer Res . 2025 Feb 10.
doi: 10.2174/0115672050365821250127055828. Online ahead of print.
Preclinical Pharmacology of CX1837, a High-Impact Ampakine with an Improved Safety Margin: Implications for Treating Alzheimer's Disease and Ischemic Stroke
Daniel P Radin 1, Sheng Zhong 2, Rok Cerne 1, Mohammed Shoaib 3, Jodi L Smith 4, Jeffrey Witkin 1 4, Arnold Lippa 1
Affiliations Expand
PMID: 39931857 DOI: 10.2174/0115672050365821250127055828
Abstract
Introduction: For over a decade, AMPA receptor allosteric potentiators (AMPAkines) have shown significant effectiveness in multiple preclinical studies related to neurodegenerative and psychiatric disorders underpinned by deficient excitatory synaptic activity. Despite promising preclinical evidence, the clinical translation of AMPAkines has been slow due to the propensity of some of these compounds to produce seizures at or around therapeutic doses. Materials and: Methods: The preclinical activity of the AMPAkine CX1837 is disclosed in the current work.
Results: CX1837 enhanced synaptic transmission in hippocampal slices in vitro and dose-dependently enhanced long-term potentiation, which is believed to control memory consolidation. CX1837 boosted performance in cognition tests, such as the novel object recognition test and the win-shift radial arm maze. CX1837 also increased attentional functioning in the 5-choice serial reaction time task involving rats. CX1837 produced positive preclinical effects at 0.01-1.0 mg/kg dose and elicited epileptic effects at 10 mg/kg dose.
Discussion: CX1837 has demonstrated to have one of the largest safety margins to date in preclinical studies. Low doses of CX1837, which produce acute increases in cognition, may potentially increase neurotrophins when given chronically. This could slow the progression of Alzheimer's disease and reverse deficits secondary to ischemic stroke.
👍️ 5
LTListener LTListener 2 days ago
Thinking of new found energy and focus and eyes on this one...

They do need to spend a little effort and update that Respire website. That remains a trainwreck and if they dont have the skills to clean it up, it would not cost much at all to hire someone to do so. Having the correct management and BOD listed, updated/link shareholder letter, update the ampakine and gabakine platform summaries, update the pipeline chart, maybe have a publications tab to highlight their achievements in peer reviews, add a professional look and touch to it. Simple yet important part of how a business communicates and presents to investing public/interested collaborators and such..

I still shm at the paradox here. The company has continually traded under 3 million market valuation long before this move to the EM and during this trip on the EM. Yet internally they value the assets north of 50 million. Having multiple ampakine candidates ready for phase 2 clinical with one having DOD funds should easily be worth 10s of million minimum. Having another gabakine candidate with a superior preclinical profile having NIH funding IND enabling studies at the advanced stages of preclinicals and readying for multiple phase 1 clinical trials most likely, is also easily worth 10s of millions... I think everyone is hoping this entity is on a course correct and soon a more fair and respectable valuation for the quality of the science, the assets will emerge and provide that flexibility and resources to really push progress on the science, expand its reach and potential. Not every effort will succeed, but some very likely will and that will have a significant impact on those who need these solutions the most. GLTA.
👍️ 3
LTListener LTListener 2 days ago
I do think there are a lot of eyes interested here. Knowing that they are focusing on getting this traded with liquidity and off the EM will heighten that interest and couple that with pipeline irons in the fire heating up in regards to initiating the phase 2, or getting grant funding for KRM-ll-81 epilepsy or investments after exiting NIH preclinicals of pain mitigation... All of it adds to the possiblity of striking a funding or BP deal for part or all of the neuromodulator pipeline, well that adds to the impetus from interested parties whether investors or potential partners.
👍️ 2
LTListener LTListener 2 days ago
Yes, so realistically the target of the conferences with institutional investors should be to fund EndeavourRx and all those activities in developing the pipeline.. I don't think anyone will be that interested in funding a chunk of change just to get this current with SEC when that money can be used to support and grow the pipeline in clinicals. Esepcially when there is a much better cost effective option in just going the alternative reporting route, which still allows them to raise small amounts of funding for corporate activities as the stock becomes more liquid then the current situation. The liquidity will be the same whether altrernate reporting or paying to be SEC reported and audited, etc.. The real deals will come when they have major investors or BP taking equity stakes in EndeavourRx or paying licensing deals. Spin that platform out to another Nasdaq shell and add a few leadership/resources and this will be positioned very nice heading into a multitude of clinicals over the next year and more.

I agree with you that when you put out such a detailed shareholder letter, which also targeted other stakeholder and collaborators, you don't just wipe your hands and do nothing for six months again... Still guessing there are deals on the table in the background that drove the silence and move to EM the past 8 months. Continual communication, more liquid trading will allow for much better and respectable valuation which in turn will also allow for flexibility in supporting the company as they negotiate deals and navigate financing whether grant funds or support capital for clinicals, etc.
👍️ 1
bigtalan bigtalan 2 days ago
I do think they see the need to have this trading, and the easiest way right now IMO is what they are looking at. The filings will need to find finance elsewhere none of the conferences is going to happen quickly. They need to get their expectations in place and a clear path in focus.
I think when they reached out on the filings it gains them more time since it then becomes a conversation between them and the options they have and can meet to satisfy the powers to be. I could see an insider stepping up or a few of them and pay what is needed and be issued the special shares. IMO I think they have alot of irons in the fire right now and they are heating up quickly. I am thinking we should see something in the next few months ( IMO ). Jeff is working on things , and has aheard an ear full from me about what we all are concerned about and want to see. The S/H letter helped alot of us , but without trading openly as you and others have stated does not give a positive look for a new investor. My point blank question was just that to him and Paul ( Investing group for oversea) with what you have done over the last 8 months and based on only what has been released to the public and shareholders would you invest in RSPI. No answer to that question from either, so hopefully they get it. Peer papers are great but at some point BP is either watching and taking notes and preparing for merger, J/V, buyout or they are still not impressed to make a move. I hope the pain compound is a smash , with no addiction side effects I would think that a BP would want that, when Opioids are phased out you would think they would want the cream of the crop to fill the void IMO
👍️ 3 ❤️ 1
LTListener LTListener 2 days ago
I think after a very positive shareholder letter, it is key that they put forth a strategy to get the liquidity back and get the stock trading again. Do you sense filing form 15 and going alternative reporting route is the likely course? I think many OTC stocks still developing their business and financial paths forward are saving the extra cash from all the audited/fees and choosing this route. They could always go back audited in the future, but honestly if they strike a larger BP deal or funding for EndeavourRx and that signfiicant pipeline, it may be more logical to then just move those assets to NASDAQ via merger & aquisition. This is really where the goal of this level of premier assets should be and I would think major institutional and BP investors would think similar to avoid the OTC stigma and such.

The alternative reporting route would allow for the liquidity to return, some recovery in market value from bottom barrell levels to more realistic valuations and provide the flexibility to then continue to develop the assets and strike solid financial/BP deals as they move closer and closer to entering clinical trials on multiple fronts. I think the 15 day decision window is Tuesday or Wednesday or what is the process related ?
👍️ 2
waterpro42 waterpro42 2 days ago
Great to hear bigt looks like filing "something" is a priority now.
👍️ 1
bigtalan bigtalan 3 days ago
The word is the conference went very well, they had very good meetings and a well received presentation , nothing moves fast from theses types of meetings. Hopefully we hear good news about the filings in the next week or two . GLTA
👍️ 4
NeutrinoKid NeutrinoKid 3 days ago
Nice, tidy summary of the current situation of Respirerx pharmaceuticals:

Feb 10, 2025

https://investorshangout.com/key-updates-and-strategies-from-respirerx-pharmaceuticals-208976-/
👍️ 4
aheadofthecurve aheadofthecurve 4 days ago
Sorry, yes it has. Haven't been visiting board as much lately. 
πŸ‘οΈ0
Lime Time Lime Time 4 days ago
Nothing matters now except that they take the necessary steps to escape the potential revocation proceedings. Nothing else matters. That's it. File a Form 15 and get TA Verified.
👍️ 1
aheadofthecurve aheadofthecurve 4 days ago
Has this been posted?
https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/what-is-in-licensing/
πŸ‘οΈ0
LTListener LTListener 4 days ago
With Monday being a holiday and Tuesday the 18th being the 15th day past the SEC notice, I would hope we would hear what the gameplan is in terms of whether they can negotiate a time period and will then provide audited filings OR just file form 15 and go unaudited and save all the extra costs that they do not need right now. The alternative reporting is the most logical since major fundraising is likely to transpire within either EndeavourRx or ResolutionRx entities which should have their own bookeeping.

Maybe eventually they IPO or M&A either of the subsidiaries onto a larger exchange and distribute equity to shareholders.
👍️ 2
Lime Time Lime Time 4 days ago
Questrade, RBC, Scotia, td, Speedtrader, a few others. But don't buy it yet until we see a Form 15 or TA Verified. They are about to face revocation proceedings.
πŸ‘οΈ0
BurgerKing82 BurgerKing82 4 days ago
Supposedly Questrade opens them.. Etrade confirmed or No?
πŸ‘οΈ0
Catpole Catpole 4 days ago
A disruptive pain killer KRM-II-81 is one of many potential disruptive discoveries. No side effects and just as effective as many prescription meds.

Read the recent PR and slide presentation and you will be pleasantly surprised with the many items in the pipeline.
πŸ‘οΈ0
hondobud hondobud 4 days ago
All IMO- The Series A & B are set up for large (long term) investors / partners with set outcomes, rules and regulations on voting and trading versus long term financing or Billions of common shares added. I'm guessing they have the two menu options for large investors to choose from, A or B or both, or possibly two (or more) investment groups. I think this is the best way in this situation to fund research and trials because it spreads out the profit and reduces the risk to everyone. Not having to pay interest or diluting the common shares is good for retail. Retail shares get last consideration in a default which I am not anticipating at all. Hoping they announce a big investor or partnership soon. GLTA HB
👍️ 1
crazy horse 0 crazy horse 0 4 days ago
From Schwab 1. Your order cannot be accepted. This security RSPI is accepting closing transactions only. (DO911)
πŸ‘οΈ0
leverage102 leverage102 4 days ago
question; I'm not a scientist, though familiar with Technologies changing molecular structures; example Molecular Cancer therapeutics . That said anyone know if Respire or related entities are using a new breakthrough technology ? If it's something I'm familiar with I may be able to weigh in.

Thanks in advance..
πŸ‘οΈ0
meixatech meixatech 4 days ago
LT - Just curious. Let's say RSPI lands 410 M (which I think is minimum). I do not understand series A, B etc. Just what would that look for us common shareholders? I am just a science guy - I do noy understand the business of biotech. But I believe, based on the science, a winner when I see one (fingers crossed anyway!).
πŸ‘οΈ0
LTListener LTListener 4 days ago
I would think they would be looking for some funding round for EndeavourRx. There are multiple candidates now at clinical stage for various medical indications of very large markets. With successful preclinical and early stage clinical results with both the ampakine and gabakine platforms, one could imagine a sizeable capital infusion as these assets are very attractive.

They were attempting a Reg A years back, but I think now with the assets spun out to subsidiaries, it may be easier for large scale funding for EndeavourRx. Noted also the change in language of the preferred shares to not consider capital raises for development as a payment event.. So clearly discussions have been ongoing about a sizeable funding round on par with the payment event levels of 15-20 million for the preferred.

I think the rocket has been moved to the launchpad... Waiting for liftoff...
👍️ 2
meixatech meixatech 4 days ago
FYI - IMO: NO doubt RSPI is positioned in the top tier, just based on the science. The key takeaway took place this last five years where the biology and pathology for many neurological indications are well understood and the molecules developed to cure.

Private biotech funding rounds in January 2025
Back to Top
First, let’s take a look at the private biotech investments in January 2025, breaking them down by value, location, funding type, and therapeutic subsector.

Biggest private biotech funding rounds by value
The first month of 2025 saw U.K.-based Verdiva Bio launch with the largest private round since October, raising a very impressive $410 million in series A funding. The company is developing a broad portfolio of oral and injectable treatments, including GLP-1 drugs, with best-in-class potential to treat obesity, cardiometabolic disorders, and related complications.

Meanwhile, the second largest private funding round in January 2025 went to Kardigan, which launched with $300 million with series A funding to develop parallel treatments to prevent and cure cardiovascular diseases, and the third biggest round went to Aviceda Therapeutics, which raised $207.5 million in series C financing to advance its lead program for geographic atrophy into pivotal trials.
👍️ 4
LTListener LTListener 5 days ago
One thing they need to do is get all their presentation material on the same page...

All three websites: Respire, Resolution and now Endeavour have a different array of information, outdated information, lacking information on who/what and a non-professional appearance. They could probably pay some college students and they could have all the information and appearance cleaned up over a weekend...lol

Hopefully we hear next week or so the gameplan to get off this EM and further updates of the pipeline as the candidates mature towards clinical trials and partnerships/JV/etc...
👍️ 2
LTListener LTListener 5 days ago
Hard to say.. I think alot of the speculative investor liquidity dances in the crypto world, yet in regards to RSPI, I continue to read where BP is interested in acquiring early stage assets in preclinical and early clinical. They have plenty of cash stockpiled over the last 5 years to utilize and load up their pipelines.

RSPI's candidates seem much better postioned then some of the past OTC pharma/biotech darlings. I doubt we can see that type of move over 3 days, but certainly over the next 3 months that is more than plausible. Getting off the EM and to a more regular trading market will get a chunk of the way there. Striking deals AND/OR initiating 1 or 2 clinical trials can easily go well beyond..
👍️ 1
peanutz peanutz 5 days ago
Finally getting some volume here. Need to get out of this EM crap. Holding mine for now
πŸ‘οΈ0
NeutrinoKid NeutrinoKid 5 days ago
Global Exploding Head Syndrome Treatment Market Research Report 2025
Code: QYRE-Auto-4X11069
Published January 2025
Pages:74

11 Key Players Profiles
11.1 Arena Pharmaceuticals
[…]
11.2 Boehringer Ingelheim
[…]
11.3 Fabre-Kramer Pharmaceuticals
[…]
11.4 Jazz Pharmaceutical
[…]
11.5 Merck & Co
[…]
11.6 Glaxo Smith Kline
[…]
11.7 Respirerx Pharmaceuticals
11.7.1 Respirerx Pharmaceuticals Company Details
11.7.2 Respirerx Pharmaceuticals Business Overview
11.7.3 Respirerx Pharmaceuticals Exploding Head Syndrome Treatment Introduction
11.7.4 Respirerx Pharmaceuticals Revenue in Exploding Head Syndrome Treatment Business (2020-2025)
11.7.5 Respirerx Pharmaceuticals Recent Development
11.8 Neurocrine Biosciences
[…]

https://reports.valuates.com/market-reports/QYRE-Auto-4X11069/global-exploding-head-syndrome-treatment
👍️ 1
Sound of Freedom Sound of Freedom 5 days ago
Can you share on what platform you purchased the shares today?
πŸ‘οΈ0
MarsMarsMars MarsMarsMars 5 days ago
Nice, Bought some toady.
πŸ‘οΈ0
aheadofthecurve aheadofthecurve 5 days ago
I agree. I was on that ride and RSPI is more legit(got the goods) , has been handled better(despite the trip to the EM) and a better share structure.
I'll sit tight. 
👍 2
BurgerKing82 BurgerKing82 5 days ago
Is it somewhat confirmed that Etrade allows the purchase of rspi? I get the Questrade point
πŸ‘οΈ0
Menace212 Menace212 5 days ago
Totally I agree with that I was in Rgbp 007 entered morning of news sold early tho at 3 cents. We can easily make it from here to a nickle. OSA compounds is already evaluated at 50m now we just need any outside entity in any form of funding to reinforce and acknowledge that sentiment.
👍 2

Your Recent History

Delayed Upgrade Clock